In case anyone is interested, Ampio bascially failed their most recent P3 clinical trial and will find it very difficult to get FDA approval for AP-013 both now and in the future. I'm also of the view that lorecivivint also failed its clinical trial, so that's bascially two of PAR's main competitors finished. One more left.
Ampios market cap was also above 500 mill, so gives a good indication of how undervalued PAR is right now IMO
https://stockhouse.com/news/press-releases/2022/04/20/ampio-provides-regulatory-update
Ampio -v- Zilosul, page-9
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 22.5¢ | $173.6K | 743.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 99346 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 131244 | 5 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |